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The Risk of Fracture in Patients Undergoing Androgen 
Deprivation May Be Overstated: Analysis of an Unselected 
Cohort of Patients
INTRODUCTION
Prostate cancer is the most common newly diagnosed 
cancer in the United States. It represents 28% of the 
estimated 1.5 million cancers diagnosed in 2010 and is 
the cause of 11% of cancer-related deaths among men 
(Jemal, Siegel et al. 2010). Androgen deprivation ther-
apy (ADT) is the main therapeutic approach for men 
with metastatic prostate cancer and it also plays a role 
in locally advanced disease in combination with radio-
therapy to prevent recurrence (Bolla, Gonzalez et al. 
1997). The use of ADT for localized prostate cancer has 
gained popularity, increasing from approximately 3.7% 
of all patients in 1991 to 30.9% in 1999 to nearly 50% in 
a 2002 cohort (Meng, Grossfeld et al. 2002; Shahinian, 
Kuo et al. 2005b). Treatment-related side effects can 
influence quality of life; they include weight gain, loss 
of lean muscle mass, impaired concentration, decreased 
libido, and hot flashes (Celestia 2004). Numerous studies 
have shown that patients treated with ADT experience 
rapid bone loss (Berruti, Dogliotti et al. 2002; Diamond, 
Higano et al. 2004; Smith, Lee et al. 2004). More recently, 
two studies reported that the bone loss related to ADT 
increases the risk of development of fractures (Shahinian, 
Kuo et al. 2005a; Smith, Peart et al. 2006).  In this study 
we examined the prevalence of fracture among men 
undergoing ADT for prostate cancer to determine if the 
fracture risk was increased among this population.
METHODS
This is a retrospective cohort study of patients treated 
with ADT in a radiation oncology and medical oncol-
ogy practice at an urban academic medical center from 
2005 to 2010. The study included 130 men who received 
ADT as primary or adjunct therapy for prostate cancer. 
Patients with evidence of bone metastases responsive to 
ADT were included, while those with androgen-indepen-
dent prostate cancer were excluded. Patients who were 
treated with ADT during the years of the study who had 
also been treated previously with ADT were included, 
and all their ADT treatment courses were analyzed. The 
primary study outcome was any clinical fracture with 
radiographic documentation at any time following the 
initiation of ADT. The study protocol was reviewed and 
approved by the St. Luke’s–Roosevelt Hospital Center 
Institutional Review Board.
Statistical Analysis
Kaplan-Meier analysis was used to generate estimates of 
FFS rates. Differences between Kaplan-Meier estimates 
of two groups were compared using the log-rank sta-
tistic. Multivariate analyses were performed with the 
use of Cox proportional-hazards regression. Factors ana-
lyzed were: presence or absence of testosterone recovery 
after ADT discontinuation, age, presence of osteoporo-
sis-related comorbidities (history of fracture as adult, 
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Objective: In this study we examined the prevalence of frac-
ture among men undergoing ADT for prostate cancer to deter-
mine if the fracture risk was increased among this population.
Background: Androgen deprivation therapy (ADT) is a thera-
peutic approach for men with various prostate cancer disease 
states. Treatment-related side effects of ADT include rapid 
bone loss. Previous studies have found that the bone loss 
related to ADT leads to the development of fractures. 
Methods: This is a retrospective cohort study of patients 
treated with ADT in a radiation oncology and medical oncol-
ogy practice at an urban academic medical center from 2005 
to 2010. Patients with evidence of bone metastases respon-
sive to ADT were included. Those with androgen-independent 
prostate cancer were excluded. 
Results: One hundred thirty patients met the inclusion criteria 
and among them only three fractures occurred during 373 
person-years of follow-up. The fracture-free survival (FFS) rate 
at three years for all was 97.7%. Excluding fractures occur-
ring within six months of ADT initiation, the FFS rate was 
100% at three years. No significant difference was demon-
strated in those screened with a pretreatment dual-emission 
X-ray absorptiometry (DEXA) scan; there was no relationship 
between the number of ADT cycles, recovery of testosterone 
to normal, or total time on ADT. Older patients, surprisingly, 
had a lower risk (p = 0.054). Patients with normal bone min-
eral density (BMD) had an FFS rate of 93.8% at three years, 
osteopenic patients had 94.7%, and patients with osteoporo-
sis and hormone-responsive metastases had 100%. 
Conclusion: The prevalence of fracture among this group is 
significantly less than what has previously been reported for 
men receiving ADT, potentially suggesting an overstatement 
of risk in the literature to date. Further prospective study with 
a larger sample size is needed. 
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diabetes, smoking, heavy alcohol use, low body weight, 
renal disease), use of medication linked to osteoporo-
sis (glucocorticoids, thyroid hormone, anticonvulsants, 
chronic heparin therapy, loop diuretics, methotrexate, 
proton-pump inhibitors, selective serotonin reuptake 
inhibitors), race, presence of metastases, number of 
follow-up visits, duration of follow-up, and duration 
of ADT. In addition, secondary analysis was performed 
looking at the impact of bone densitometry screening 
on the incidence of fracture. Analysis was performed 
using the SPSS Statistics program v. 14.0.
RESULTS
One hundred thirty patients met the criteria for inclusion 
in the study. Their characteristics are listed in Table 1.
The primary endpoint of fracture was experienced by 3 
of the 130 patients. The details of these fractures are 
listed in Table 2. All of the fractures occurred soon after 
ADT initiation, with five months being the longest dura-
tion of treatment prior to fracture. Further, all fractures 
occurred following falls and none occurred in patients 
with metastatic disease. 
The FFS rate for all patients at three years was 95.1%. 
If fractures that occurred within six months of ADT ini-
tiation, which were unlikely to be related to ADT, are 
excluded, the FFS rate was 100%. When the cohort 
was stratified based on bone mineral density (BMD) 
screening, two of the three fractures occurred among 
those monitored with DEXA scans. The difference in 
FFS between those screened with DEXA scans prior 
to ADT versus those not screened was not significant. 
Surprisingly, the fractures did not correlate with worse 
BMD measurements, as might be expected. At three 
years, patients with normal BMD had an FFS rate of 
93.8%, osteopenic patients had an FFS of 94.7%, and 
patients with osteoporosis and hormone-responsive 
metastases had an FFS of 100%. These differences were 
not statistically significant.
One hundred ten patients underwent a single course of 
ADT. Among those, the median duration of therapy was 
nine months. Two fractures occurred within the group 
undergoing only one course of treatment (9 months and 
31 months of ADT, respectively). However, the expected 
dose-response relationship that has been previously dem-
onstrated did not manifest in our cohort, as both fractures 
occurred within the first five months of ADT initiation. 
Furthermore, among the 20 patients who received more 
than one course of treatment (median 36 months), only 
one fracture occurred. This fracture was traumatic and 
occurred three months after ADT initiation.
Bone densitometry was performed on 41 patients; it 
identified 6 patients as osteoporotic, 19 as osteope-
nic, and 16 with normal BMD. Among the monitored 
TABLE 1. CHARACTERISTICS OF THE PATIENTS
Age at Diagnosis (y) 67.7 ± 1.3
Race  
Black 27.7%
Hispanic 26.1%
White 35.4%
Other 10.8%
Median Follow-up Visits (n) 15
Median Follow-up (m) 26
Total Follow-up (person-months) 4474
AJCC Stage (n)  
I 16
II 84
III 22
IV 8
Gleason Score (n)  
5–6 32
7–8 79
9–10 18
Unknown 1
Total ADT Duration (m)  
<6 13
6–8 39
9–12 49
>12 29
Courses of ADT (n)
1 110
2 4
3 11
>3 5
Presence of Osteoporosis Risk Factors  
Lifestyle/medical 53.85%
Medication 20.77%
Other Treatments (n)  
IMRT 107
Brachytherapy 15
Both 4
Testosterone Recovery to Normal 62.8%
Pretreatment DEXA Scan 31.5%
n = number, y = years, m = months
The Einstein Journal of Biology and Medicine 53
The Risk of Fracture in Patients Undergoing Androgen Deprivation May Be Overstated
4ORIGINAL ARTICLES
patients, five of the six osteoporotic patients (one 
declined), three of the osteopenic patients, and one 
with normal BMD (whose use predated ADT initiation) 
received treatment with a bisphosphonate. None of the 
nine in the bisphosphonate treatment group experi-
enced a fracture during follow-up.
Secondary analyses were also performed, specifically 
looking at testosterone recovery, age, presence of 
osteoporosis risk factors (lifestyle, medical, or medica-
tion), race, presence of metastases, number of follow-
up visits, duration of follow-up, or duration of ADT, and 
the relation of these factors to fracture. None of the 
analyses demonstrated a statistically significant differ-
ence between the two groups, although older patients, 
surprisingly, demonstrated a strong trend toward lower 
fracture risk (p = 0.054). 
DISCUSSION
In our cohort of patients, the fracture prevalence of 
men receiving ADT was significantly less than previously 
reported in large population-based studies. Shahinian 
and colleagues found fracture prevalence to be nearly 
20% , while Smith and colleagues reported that the rate 
of any fracture was 7.91/100 person-years at risk for men 
receiving ADT. Our study had a fracture prevalence of 
2.3% and a rate of 0.8/100 person-years. Based on the 
reported rate of fracture from those two previous stud-
ies, our group had markedly fewer than was anticipated 
(Table 3). Further, all of our fractures, which occurred 
within five months of initiation of treatment, would 
not have been included in the Shahinian et al. (2005a) 
study. We included the fractures in the first year, as the 
data show that the most accelerated bone loss occurs 
in the first six months following the initiation of ADT 
(Greenspan, Coates et al. 2005).
In addition to analyzing fracture incidence in terms 
of person-years, we looked at fractures using Kaplan-
Meier estimates. Shahinian et al. (2005a) had a three-
year FFS rate of approximately 90% within their group 
that received one to four doses of ADT, while the group 
that received greater than nine doses had an FFS rate of 
about 85%. This is in stark contrast to our results, which 
demonstrated an overall three-year FFS rate of 95.1%, 
with 90% of our cohort receiving at least six months 
of ADT. Furthermore, the FFS rate increased to 100% 
if we eliminated fractures occurring within the first 12 
months as in the Shahinian study.
There are a number of potential explanations for the 
marked difference demonstrated in our cohort versus 
the previous studies. One possibility is that the patients 
in this study were on average younger than those in the 
other studies, and age has previously been reported as a 
risk factor for increased fracture risk, despite the oppo-
site finding in our cohort (Kanis 2002). Our study had a 
more racially diverse population when compared with 
the predominantly Caucasian groups seen in the previ-
ous studies, and Caucasian race has also been shown to 
increase fracture risk (Baron, Barrett et al. 1994). Lastly, 
physician discretion has the potential to affect results. 
Compared with the large population-based studies that 
included patients from 1992 to 1997 (Shahinian, Kuo et 
al. 2005a) and 1998 to 2003 (Smith, Peart et al. 2006), 
this study included patients of only two physicians from 
2005 to 2010. These physicians perhaps had greater dis-
cretion in prescribing ADT to their patients, based on 
comorbidities and the literature suggesting a correla-
tion between ADT and bone health as early as 1995 
(Eriksson, Eriksson et al. 1995).
This study also failed to demonstrate a benefit from 
screening patients with DEXA scans prior to ADT. 
Undoubtedly, preventing fractures in men undergoing 
ADT is necessary, as fractures have been shown to increase 
cost of care (Krupski, Foley et al. 2007) and decrease 
length of survival (Oefelein, Ricchiuti et al. 2002). A 2010 
study using a Markov state-transition model even sug-
gested that the use of DEXA screening is cost effective in 
preventing fractures (Ito, Elkin et al. 2010), but the data 
from this study call that into question.
TABLE 3. ACTUAL VS. EXPECTED FRACTURES
 Fractures
Observed 3
Expected (Shahinian et al.) 25.22
Expected (Smith et al.) 29.49
TABLE 2. FRACTURE CHARACTERISTICS
Fracture 1 Fracture 2 Fracture 3
Types of Fracture Fracture of ankle s/p fall Fracture of R 8th & 9th rib and  
R inferior orbit s/p fall
Fracture of ankle s/p fall
Length of Time from ADT 
Initiation to Fracture (m)
3 3 5
Comorbidities None None SSRI use
Demographic 50 y/o Caucasian 61 y/o AA 64 y/o Caucasian
Metastatic Disease No No No
54  EJBM, Copyright © 2012
The Risk of Fracture in Patients Undergoing Androgen Deprivation May Be Overstated
4ORIGINAL ARTICLES
The retrospective design of this study is a limitation. 
Also, the cohort of patients was limited in number and 
geographically confined to one hospital. Duration of 
patient follow-up, while the same as in the Smith study, 
was a limiting factor. Lastly, the number of fractures 
in the study cohort limits the analysis and conclusions 
regarding DEXA screening.
In conclusion, the prevalence of fracture in the study 
group is significantly less than what has previously been 
reported for patients receiving ADT, potentially suggest-
ing an overstatement of risk. Further prospective study 
with a larger sample size is needed. 
REFERENCES
Baron, J.A., Barrett, J., Malenka, D., Fisher, E., Kniffin, W., Bubolz, T., and 
Tosteson, T. (1994). Racial differences in fracture risk. Epidemiology 5(1):42–47.
Berruti, A., Dogliotti, L., Terrone, C., Cerutti, S., Isaia, G., Tarabuzzi, R., 
Reimondo, G., Mari, M., Ardissone, P., De Luca, S., Fasolis, G., Fontana, D., 
Rossetti, S.R., and Angeli, A. (2002). Changes in bone mineral density, lean 
body mass and fat content as measured by dual energy X-ray absorptiometry 
in patients with prostate cancer without apparent bone metastases given 
androgen deprivation therapy. J Urol 167(6):2361–2367.
Bolla, M., Gonzalez, D., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., 
Bernier, J., Kuten, A., Sternberg, C., Gil, T., Collette, L., and Pierart, M. (1997). 
Improved survival in patients with locally advanced prostate cancer treated 
with radiotherapy and goserelin. N Engl J Med 337(5):295–300.
Celestia, S. H. (2004). “Understanding treatments for bone loss and bone 
metastases in patients with prostate cancer: a practical review and guide for 
the clinician.” The Urologic clinics of North America 31(2): 331-352.
Diamond, T.H.,, C.S., Smith, M.R., Guise, T.A., and Singer, F.R. (2004). 
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation 
therapy: Recommendations for diagnosis and therapies. Cancer 100(5):892–
899.
Eriksson, S., Eriksson, A., Stege, R., and Carlström, K. (1995). Bone mineral 
density in patients with prostatic cancer treated with orchidectomy and with 
estrogens. Calcif Tissue Int 57(2):97–99.
Greenspan, S.L., Coates, P., Sereika, S.M., Nelson, J.B., Trump, D.L., and Resnick, 
N.M. (2005). Bone loss after initiation of androgen deprivation therapy in 
patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–6417.
Higano, C.S. (2004). Understanding treatments for bone loss and bone metas-
tases in patients with prostate cancer: A practical review and guide for the 
clinician. Urol Clin North Amer 31(2):331–352.
Ito, K., Elkin, E.B., Girotra, M., and Morris, M.J. (2010). Cost-effectiveness of 
fracture prevention in men who receive androgen deprivation therapy for 
localized prostate cancer. Ann Intern Med 152(10):621–629.
Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA 
Cancer J Clin 60(5):277–300.
Kanis, J.A. (2002). Diagnosis of osteoporosis and assessment of fracture risk. 
Lancet 359(9321):1929–1936.
Krupski, T.L., Foley, K.A., Baser, O., Long, S., Macarios, D., and Litwin, M.S. 
(2007). Health care cost associated with prostate cancer, androgen deprivation 
therapy and bone complications. J Urol 178(4 pt. 1):1423–1428.
Meng, M.V., Grossfeld, G.D., Sadetsky, N., Mehta, S.S., Lubeck, D.P., and Carroll, 
P.R. (2002). Contemporary patterns of androgen deprivation therapy use for 
newly diagnosed prostate cancer. Urology 60(3 suppl.1):7–11.
Oefelein, M.G., Ricchiuti, V., Conrad, W., and Resnick, M.I. (2002). Skeletal frac-
tures negatively correlate with overall survival in men with prostate cancer. J 
Urol 168(3):1005–1007.
Shahinian, V.B., Kuo, Y.F., Freeman, J.L., and Goodwin, J.S. (2005a). Risk of frac-
ture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–
164.
Shahinian, V.B., Kuo, Y.F., Freeman, J.L., Orihuela, E., and Goodwin, J.S. (2005b). 
Increasing use of gonadotropin-releasing hormone agonists for the treatment 
of localized prostate carcinoma. Cancer 103(8):1615–1624.
Smith, M.R., Lee, W.C., Krupsi, T., Brandman, J., Wang, Q., Botteman, M., 
Pashos, C., and Litwin, M. (2004). Association between androgen deprivation 
therapy and fracture risk: A population-based cohort study in men with non-
metastatic prostate cancer. J Clin Oncol (Meeting Abstracts) 22(14 suppl.):4507.
Smith, M.R., Boyce, S.P., Moyneur, E., Duh, M.S., Raut, M.K., and Brandman, J. 
(2006). Risk of clinical fractures after gonadotropin-releasing hormone agonist 
therapy for prostate cancer. J Urol 175(1):136–139.
Corresponding Author: Address correspondence to Ronald D. Ennis, MD 
(REnnis@chpnet.org), Department of Radiation Oncology, St. Luke’s–Roosevelt 
Hospital Center, 1000 Tenth Avenue, Lower Level, New York, NY 10019. 
Conflict of Interest Disclosures: The authors have completed and submitted 
the ICMJE Form for Disclosure of Potential Conflicts of Interest. No conflicts 
were noted.
 
Previous Presentation: This research was presented at the 2011 ASCO 
Genitourinary Cancers Symposium, Orlando, FL, February 2011
